ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.10+0.06 (+5.77%)
Close on Nov 17, 2026Market cap $332.56MP/E –Yield –
ProKidney operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ProKidney's operating income for the twelve months ending Jun 30, 2026 was -$177.22M. For fiscal 2025 it was -$165.01M. The highest annual figure on record is -$27.02M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$165.01M | – |
| FY2024 | Dec 31, 2024 | -$183.68M | – |
| FY2023 | Dec 31, 2023 | -$151.52M | – |
| FY2022 | Dec 31, 2022 | -$153.01M | – |
| FY2021 | Dec 31, 2021 | -$55.11M | – |
| FY2020 | Dec 31, 2020 | -$27.02M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$48.37M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$45.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$51.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$48.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$43.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$40.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.24M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.74M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$143 | – |
See a number that looks wrong?